Get the Stockscreener App
1.94
2.51%
-0.05
Clearmind Medicine Inc stock is traded at $1.94, with a volume of 192.29K.
It is down -2.51% in the last 24 hours and down -38.22% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$1.99
Open:
$1.9
24h Volume:
192.29K
Relative Volume:
0.08
Market Cap:
$2.88M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.0108
EPS:
-179.3009
Net Cash Flow:
$-5.60M
1W Performance:
-4.43%
1M Performance:
-38.22%
6M Performance:
-92.24%
1Y Performance:
-99.52%
1-Day Range:
$1.81
$1.99
1-Week Range:
$1.74
$2.25
52-Week Range:
$1.74
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.94 | 2.96M | 0 | -6.64M | -5.60M | -179.30 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com South Africa
Clearmind Medicine comments on federal psychedelic guidance - Investing.com UK
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - The Manila Times
Clearmind reports mucoadhesion results for intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine Reports Improved Mucoadhesion for Intranasal MEAI Formulation in Ex Vivo Study - Quiver Quantitative
Clearmind shares CMND-100 trial insights - grafa.com
Clearmind reports positive early data from alcohol disorder trial - Investing.com UK
Clearmind's trial shows promising safety and po... - Pluang
Clearmind Medicine Reports Positive Early Experience in Phase I/IIa Trial of Non-Hallucinogenic MEAI for Alcohol Use Disorder - Quiver Quantitative
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Yahoo Finance Singapore
Clearmind Medicine (Nasdaq: CMND) details neuroplastogen-based response to U.S. addiction RFI - Stock Titan
Clearmind Medicine Submits Formal Response To HHS RFI Highlighting MEAI-Based Candidate CMND-100 For Alcohol Use Disorder And Binge Behaviors - marketscreener.com
Clearmind submits addiction treatment proposal to U.S. HHS - Investing.com India
Clearmind submits MEAI addiction treatment prop... - Pluang
Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Canada
Clearmind Medicine Submits Response to HHS RFI Highlighting MEAI-Based CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative - The Manila Times
Clearmind Medicine (CMND) reports successful intranasal MEAI feasibility study - Stock Titan
Clearmind reports MEAI intranasal study progress - grafa.com
Clearmind Medicine : Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI - marketscreener.com
CMND Stock Slides As Traders Gauge Cash Runway And Volatility - StocksToTrade
Clearmind advances intranasal delivery studies for addiction drug By Investing.com - Investing.com Canada
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI - The Manila Times
Clearmind Medicine Reports Successful Formulation Feasibility for Intranasal MEAI Development Program for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Clearmind Medicine receives U.S. patent for binge behavior treatment - Investing.com UK
Clearmind Medicine receives U.S. patent for binge behavior treatment By Investing.com - Investing.com Australia
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength - The Manila Times
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Price to earnings forward of Clearmind Medicine Inc. – MUN:CWY0 - TradingView
Price to earnings forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Enterprise value to revenue forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Price to sales forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Price to book forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA-Regulated Phase I/II Trial - marketscreener.com
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clearmind completes treatment phase of alcohol disorder trial - Investing.com UK
Clearmind Medicine (CMND) Completes Phase I/II Trial for Alcohol Use Disorder - GuruFocus
Clearmind completes treatment phase of alcohol disorder trial By Investing.com - Investing.com South Africa
Form 6K Clearmind Medicine Inc For: 22 June By Investing.com - Investing.com Nigeria
Clearmind Medicine Completes Treatment for All Participants in Part A of Phase I/II Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial - The Manila Times
Clearmind Medicine (Nasdaq: CMND) hits CMND-100 Phase I/II milestone - Stock Titan
Insider Selling: Financial Hrt Sells Shares of Clearmind Medicine Inc (CMND) - GuruFocus
HRT Financial LP trims Clearmind Medicine (CMND) stake with 22,139-share sale - Stock Titan
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators - The Manila Times
Clearmind Medicine (NASDAQ: CMND) secures U.S. patent for MEAI binge behavior regulators - Stock Titan
Clearmind Medicine Inc Share PriceCMND, RNS News, Articles, Quotes, & Charts (NASDAQ:CMND) - Proactive financial news
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clearmind Medicine Inc Stock (CMND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Jun 15 '26 |
Sale |
3.32 |
3,183 |
10,568 |
103,492 |
| HRT FINANCIAL LP | 10% Owner |
Jun 12 '26 |
Sale |
3.36 |
2,102 |
7,063 |
106,675 |
| HRT FINANCIAL LP | 10% Owner |
Jun 10 '26 |
Buy |
0.15 |
2,159,052 |
330,335 |
2,063,266 |
| HRT FINANCIAL LP | 10% Owner |
Jun 11 '26 |
Sale |
0.12 |
225,191 |
27,698 |
1,838,075 |
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):